WO2020085504A1 - 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 - Google Patents

光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 Download PDF

Info

Publication number
WO2020085504A1
WO2020085504A1 PCT/JP2019/042005 JP2019042005W WO2020085504A1 WO 2020085504 A1 WO2020085504 A1 WO 2020085504A1 JP 2019042005 W JP2019042005 W JP 2019042005W WO 2020085504 A1 WO2020085504 A1 WO 2020085504A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
substituent
general formula
salt
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2019/042005
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
俊浩 坂本
倫広 山本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of WO2020085504A1 publication Critical patent/WO2020085504A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

  • the present invention relates to a method for producing a chloroazole carboxylate derivative.
  • the Sandmeyer reaction or the Sandmeyer-like reaction is carried out by using a copper (I) salt or the like to give an aromatic amine by using a diazonium salt obtained by diazotizing an aromatic primary amine derivative as an active intermediate. It is a reaction of converting to a halogen or cyan derivative. This reaction may be performed without using a copper (I) salt, and a Balz-Schiemann reaction for obtaining a fluoride by thermally decomposing a diazonium ion with tetrafluoroboric acid and a treatment with potassium iodide Then, a reaction to give iodide can be mentioned. These reactions are also included in the Sandmeyer reaction in a broad sense, and are sometimes called similar to the Sandmeyer reaction.
  • Non-patent documents 1-4 As an example of fluorinating a 4-halogeno-1H-imidazole derivative, an aqueous solution of tetrafluoroboric acid is used as a fluorine source, and ethyl 4-amino-1H-imidazole-5-carboxylate to 4-fluoro-1H is used. -It has been reported that imidazole-5-carboxylate can be obtained (Non-patent documents 1-4). However, in the method of removing boric acid by esterification with alcohols or the like, when the content of boric acid is high, it is necessary to use a large amount of an organic solvent, and a method for industrial mass production. There is also a problem that is not appropriate. Besides, there is also a report that the yield is improved by using an ionic liquid (Non-Patent Document 5).
  • ethyl 4-chloro-1H-imidazole-5-carboxylate can be obtained from ethyl 4-amino-1H-imidazole-5-carboxylate using copper (I) chloride.
  • this reaction has a low yield (Non-Patent Document 6).
  • diazo which is a reaction intermediate, is isolated, and 0.1N hydrochloric acid or 1N hydrochloric acid is used as a starting material to obtain 49.5% of the corresponding chloro derivative.
  • the reaction was described to require stirring for 18 days (Non-Patent Document 7).
  • the corresponding chloro derivative can be obtained by using this reaction intermediate, diazo, as a raw material, and using dichloromethane and irradiation with light (300 W, 300-600 nm). It has been reported that this reaction is from an isolated diazo, it is a reaction that seems to generate a radical from dichloromethane using light, and that dichloromethane is an environmentally hazardous solvent. Therefore, it is not suitable for safe mass synthesis in consideration of the environment (Non-Patent Document 8).
  • the diazo compound is isolated as a reaction intermediate by the method described in the prior art. There is a need. Therefore, the thermal stability of the diazo compound, which is a reaction intermediate, must be taken into consideration in the large-scale scale synthesis of pharmaceutical raw materials. It is generally said that it is safe if the exothermic peak in the analysis by DSC is higher than the reaction temperature + 100 ° C. or higher, but methyl 4-diazoimidazole-5, which is the reaction intermediate of the Sandmeyer reaction of the present invention.
  • Carboxylate has a heat generation of about 1450 J / g at around 133 ° C. as analyzed by DSC (Differential Scanning Calorimeter) (FIG. 1), so it is desirable to keep it at least 33 ° C. or lower.
  • DSC Different Scanning Calorimeter
  • the production of the methyl 4-chloro-1H-imidazole-5-carboxylate compound using the Sandmeyer reaction involves extraction, concentration, etc. when the diazo compound or diazonium compound is isolated and purified. Since there is a high possibility that the temperature will exceed the safe range during work and there is a risk of explosion, it is desirable to obtain the chloroazole carboxylate derivative without isolating the diazo compound.
  • X 1 represents C, N, O or S
  • X 2 represents C or N
  • R 1 represents a C1-C6 alkyl group which may have a substituent
  • R 2 is a hydrogen atom, a halogen atom, a cyano group, a nitro group, a carboxyl group, a C1-C6 alkyl group which may have a substituent, a C2-C6 alkenyl group which may have a substituent, or a substituent.
  • a membered unsaturated heterocyclic group, l, m and n each independently represent 0 or 1.
  • l + m + n is 1, 2 or 3, Between X 1 and X 2
  • a method for producing a compound represented by the formula (1) or a salt thereof which comprises irradiating a reaction system containing the compound represented by the general formula (II) or a salt thereof, a diazotizing agent, and hydrochloric acid with light. how to.
  • a reaction system containing the compound represented by the general formula (II) or a salt thereof, a diazotizing agent, and hydrochloric acid with light how to.
  • a chloroazole carboxylate derivative represented by the general formula (II) to the general formula (I) or a salt thereof can be produced without isolating a diazo compound or a diazonium compound salt. Therefore, considering the DSC exothermic peak of the above-mentioned diazo compound, the method of the present invention is useful in that the compound represented by the general formula (I) or a salt thereof can be safely produced. Further, by using hydrochloric acid, it is possible to provide a method for producing a compound represented by the general formula (I) or a salt thereof which is excellent in safety and economy and has a low environmental load. Further, by shortening the reaction time by irradiation with light, it is possible to simply and efficiently provide a method for producing the compound represented by the general formula (I) or a salt thereof.
  • Cx-Cy in the description of the group in the present specification means a group having carbon numbers x to y.
  • C1-C6 alkyl group means an alkyl group having 1 to 6 carbon atoms
  • C6-C14 aromatic hydrocarbon oxy group means an oxy group to which an aromatic hydrocarbon group having 6 to 14 carbon atoms is bound.
  • AB member means that the number of atoms constituting the ring (the number of ring members) is AB.
  • the “4- to 10-membered saturated heterocyclic group” means a saturated heterocyclic group having 4 to 10 ring members.
  • C means a carbon atom
  • N means a nitrogen atom
  • S means a sulfur atom
  • O means an oxygen atom
  • H means a hydrogen atom.
  • a double line means a double bond
  • a broken line on one side of the double line means a single bond or a double bond.
  • substituted for example, a hydrogen atom, a halogen atom, a cyano group, a nitro group, an amino group, a hydroxyl group, an oxo group, a carbonyl group, a carboxyl group, a carbamoyl group.
  • examples of the “halogen atom” specifically include a chlorine atom, a bromine atom, a fluorine atom and an iodine atom, preferably a chlorine atom, a fluorine atom and a bromine atom, more preferably a chlorine atom. is there.
  • alkyl group refers to a linear or branched saturated hydrocarbon group, and examples thereof include a C1-C10 alkyl group.
  • C1-C10 alkyl group refers to a linear or branched saturated hydrocarbon group having 1 to 10 carbon atoms, such as methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group.
  • haloalkyl group refers to the above alkyl group having at least one halogen atom (preferably 1 to 10 and more preferably 1 to 3), and examples thereof include a fluoromethyl group and a difluoromethyl group.
  • Trifluoromethyl group Trifluoromethyl group, trichloromethyl group, 1-fluoroethyl group, 1,1-difluoroethyl group, 1,1,1-trifluoroethyl group, 1-fluoro-n-propyl group, 1,1,1-tri Examples thereof include C1-C6 haloalkyl groups such as fluoro-n-propyl group, perfluoro-n-propyl group and perfluoroisopropyl group, preferably trifluoromethyl group, 1-fluoroethyl group, 1,1-difluoroethyl group. , 1,1,1-trifluoroethyl group.
  • hydroxyalkyl group refers to the above alkyl group having at least one hydroxyl group (preferably 1 to 10 and more preferably 1 to 2), and examples thereof include a hydroxymethyl group and a hydroxyethyl group. Examples thereof include C1-C6 hydroxyalkyl groups such as 1-hydroxypropyl group and 2-hydroxybutyl group.
  • the “cyanoalkyl group” is the alkyl group having at least one (preferably 1 to 10, more preferably 1 to 2) cyano group, and examples thereof include a cyanomethyl group, a cyanoethyl group, and Examples include C1-C6 cyanoalkyl groups such as -cyanopropyl group and 2-cyanobutyl group.
  • cycloalkyl group refers to a monocyclic or polycyclic saturated hydrocarbon group having 3 to 10 carbon atoms, for example, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group.
  • C3-C10 cycloalkyl groups such as cyclodecyl group, and preferably cyclopropyl group, cyclobutyl group and cyclopentyl group, more preferably cyclobutyl group and cyclopentyl group.
  • the “cycloalkenyl group” means a monocyclic, bridged cyclic or polycyclic non-cyclic group having at least one carbon-carbon double bond (eg, 1 to 2, preferably 1).
  • the saturated hydrocarbon group include C4-C10 cycloalkenyl groups such as cyclobutenyl group, cyclopentenyl group, cyclohexenyl group, cycloheptenyl group, cyclodecenyl group, and the like, preferably cyclobutenyl group, cyclopentenyl group, cyclohexenyl group.
  • cycloalkyl-alkyl group refers to the above alkyl group having at least one cycloalkyl group, and examples thereof include a cyclopropylmethyl group, a cyclobutylmethyl group, a cyclopentylmethyl group, a cyclohexylmethyl group and a cyclohexyl group.
  • examples thereof include C3-C10 cycloalkyl-C1-C4 alkyl groups such as isopropyl group, cyclohexyl 1-methyl-4-isopropyl group and cycloheptylmethyl group, and cyclohexylmethyl group is preferable.
  • the “unsaturated hydrocarbon group” refers to a linear or branched unsaturated hydrocarbon group containing at least one carbon-carbon double bond or triple bond, for example, a vinyl group
  • examples thereof include C2-C10 unsaturated hydrocarbon groups such as allyl group, methylvinyl group, 1-propenyl group, butenyl group, pentenyl group, hexenyl group, ethynyl group and 2-propynyl group, preferably at least one carbon-carbon group.
  • It is a C2-C6 linear or branched hydrocarbon group containing a double bond or a triple bond, more preferably a vinyl group, an allyl group or a 1-propenyl group, and most preferably a vinyl group.
  • alkenyl group refers to a linear or branched unsaturated hydrocarbon group having at least one double bond (eg, 1 to 2, preferably 1),
  • vinyl group allyl group, 1-propenyl group, 2-methyl-2-propenyl group, isopropenyl group, 1-, 2- or 3-butenyl group, 2-, 3- or 4-pentenyl group, 2-methyl
  • Examples thereof include C2-C10 alkenyl groups such as 2-butenyl group, 3-methyl-2-butenyl group and 5-hexenyl group, preferably vinyl group, allyl group, 1-propenyl group, 2-methyl-2-propenyl group.
  • a C2-C6 alkenyl group such as a group, and most preferably a vinyl group.
  • alkynyl group refers to a linear or branched unsaturated hydrocarbon group having at least one triple bond (eg, 1 to 2, preferably 1), for example, C2-C10 alkynyl groups such as ethynyl group, 1- or 2-propynyl group, 1-, 2- or 3-butynyl group, 1-methyl-2-propynyl group, and the like, preferably ethynyl group, 2-propynyl group.
  • a C2-C6 alkenyl group such as a group, and most preferably a 2-propynyl group.
  • alkoxy group refers to an oxy group having the above alkyl group, and includes, for example, methoxy group, ethoxy group, n-propoxy group, isopropoxy group, n-butoxy group, isobutoxy group, sec-butoxy group, Examples thereof include C1-C6 alkoxy groups such as tert-butoxy group, pentyloxy group, isopentyloxy group and hexyloxy group, preferably methoxy group and ethoxy group, and more preferably methoxy group.
  • haloalkoxy group refers to the above alkoxy group having at least one halogen atom (preferably 1 to 13, more preferably 1 to 3), and examples thereof include a fluoromethoxy group and a difluoromethoxy group.
  • Trifluoromethoxy group Trifluoromethoxy group, trichloromethoxy group, fluoroethoxy group, 1,1-difluoroethoxy group, 1,1,1-trifluoroethoxy group, monofluoro-n-propoxy group, perfluoro-n-propoxy group, per Examples thereof include C1-C6 haloalkoxy groups such as fluoro-isopropoxy group, and preferred are fluoromethoxy group, difluoromethoxy group and trifluoromethoxy group.
  • alkoxy-alkyl group refers to the above alkyl group having at least one of the above alkoxy groups, and includes, for example, methoxymethyl group, ethoxymethyl group, methoxyethyl group, ethoxyethyl group, methoxypropyl group, methoxy.
  • Examples include C1-C4 alkoxy-C1-C10 alkyl groups such as -n- group, methoxypentyl group, methoxyhexyl group and methoxyheptyl group, propoxyethyl group, butoxyethyl group, and preferably methoxymethyl group, ethoxymethyl group,
  • a C1-C2 alkoxy-C1-C3 alkyl group such as a methoxyethyl group and an ethoxyethyl group is more preferable, and a methoxymethyl group and a methoxyethyl group are more preferable.
  • cycloalkoxy group refers to an oxy group having the above cycloalkyl group, and examples thereof include C3-C10 cyclo groups such as cyclopropoxy group, cyclobutoxy group, cyclopentyloxy group, cyclohexyloxy group and cycloheptyloxy group. Examples thereof include an alkoxy group, preferably a cyclobutoxy group, a cyclopentyloxy group, and a cyclohexyloxy group.
  • cycloalkyl-alkoxy group refers to the above alkoxy group having at least one of the above cycloalkyl group, and examples thereof include a cyclopropylmethoxy group, a cyclobutylmethoxy group, a cyclopentylmethoxy group, a cyclohexylmethoxy group and a cycloalkyl group. Examples thereof include C3-C10 cycloalkyl group-C1-C4 alkoxy group such as heptylmethoxy group, and cyclohexylmethoxy group is preferable.
  • cycloalkyl-haloalkyl group refers to the above haloalkyl group having at least one of the above cycloalkyl group, and examples thereof include a cyclopropylfluoromethyl group, a cyclobutylfluoromethyl group, a cyclopentylfluoromethyl group and a cyclohexylfluoro group. Examples thereof include C3-C10 cycloalkyl group-C1-C4 haloalkyl group such as methyl group and cycloheptylfluoromethyl group, and cyclohexylfluoromethyl group is preferable.
  • alkylthio group refers to a thioxy group having the above alkyl group, and examples thereof include methylthio group, ethylthio group, n-propylthio group, isopropylthio group, n-butylthio group, isobutylthio group and tert-butylthio group.
  • Group, a C1-C6 alkylthio group such as an n-pentylthio group, an isopentylthio group, a hexylthio group, and the like, and a methylthio group and an ethylthio group are preferable.
  • cycloalkyl-alkylthio group refers to the above alkylthio group having at least one of the above cycloalkyl group, and includes, for example, a cyclopropylmethylthio group, a cyclobutylmethylthio group, a cyclopentylmethylthio group, a cyclohexylmethylthio group and a cyclohexylmethylthio group.
  • Examples thereof include a C3-C7 cycloalkyl-C1-C4 alkylthio group such as a heptylmethylthio group, and a cyclohexylmethylthio group is preferable.
  • alkylamino group refers to an amino group having one or two of the above alkyl groups, and specifically, for example, methylamino group, ethylamino group, dimethylamino group, diethylamino group, ethylmethyl group.
  • examples thereof include a C1-C6 alkylamino group such as an amino group, and a methylamino group, a dimethylamino group and a methylethylamino group are preferable.
  • the “monoalkylamino group” refers to an amino group having one alkyl group, and examples thereof include a methylamino group, an ethylamino group, an n-propylamino group, an isopropylamino group and an n-butylamino group.
  • C1-C6 monoalkylamino groups such as isobutylamino group, tert-butylamino group, n-pentylamino group, isopentylamino group and hexylamino group, and preferably methylamino group.
  • dialkylamino group refers to an amino group having two alkyl groups, and examples thereof include a dimethylamino group, a diethylamino group, a di (n-propyl) amino group, a diisopropylamino group and a di (n- C2- such as butyl) amino group, diisobutylamino group, di (tert-butyl) amino group, di (n-pentyl) amino group, diisopentylamino group, dihexylamino group, methylethylamino group, methylisopropylamino group A C12 dialkylamino group is mentioned, and a dimethylamino group is preferable.
  • alkylaminoalkyl group refers to the alkyl group having at least one of the alkylamino groups, and examples thereof include a methylaminomethyl group, a methylaminoethyl group, an ethylaminomethyl group, an ethylaminopropyl group and the like.
  • C1-C6 alkylamino-C1-C6 alkyl group is preferable, and dimethylaminomethyl group and dimethylaminoethyl group are preferable.
  • cycloalkyl-alkylamino group refers to the above-mentioned alkylamino group having the above cycloalkyl group, wherein the alkyl moiety of the alkylamino group is substituted with a cycloalkyl group.
  • Examples thereof include C3-C7 cycloalkyl-C1-C4 alkylamino groups such as cyclopropylmethylamino group, cyclobutylmethylamino group, cyclopentylmethylamino group, cyclohexylmethylamino group and cycloheptylmethylamino group, and preferably cyclobutylmethyl An amino group and a cyclohexylmethylamino group.
  • the “aromatic hydrocarbon group” is a cyclic substituent consisting of carbon and hydrogen having an unsaturated bond, and 4e + 2 (e is an integer of 1 or more) electrons in the cyclic ⁇ electron system.
  • e is an integer of 1 or more electrons in the cyclic ⁇ electron system.
  • the “aralkyl group” refers to the alkyl group substituted with the aromatic hydrocarbon group, and examples thereof include a benzyl group, a phenylethyl group, a phenylpropyl group, a naphthylmethyl group and a naphthylethyl group.
  • a C7-C16 aralkyl group can be mentioned, and a benzyl group is preferable.
  • aralkyloxy group refers to an oxy group having the above aralkyl group, and examples thereof include C7-C20 aralkyloxy groups such as benzyloxy group, phenethyloxy group, naphthylmethyloxy group and fluorenylmethyloxy group. Groups.
  • acyl group refers to a carbonyl group having the above-mentioned alkyl group or aryl group, for example, a carbonyl group having a C1-C16 substituent such as a methylcarbonyl group, an ethylcarbonyl group and a phenylcarbonyl group. And preferably a methylcarbonyl group or an ethylcarbonyl group.
  • alkylcarbonyl group refers to a carbonyl group having the above-mentioned alkyl group, and is also included in another name of acyl group.
  • the C1-C6 alkylcarbonyl group refers to a (C1-C6 alkyl) carbonyl group.
  • arylcarbonyl group refers to a carbonyl group having the above-mentioned aromatic hydrocarbon group, and is also included in the alias group acyl.
  • Examples thereof include (C6-C20 aryl) carbonyl groups such as an nylcarbonyl group, an indanylcarbonyl group and a phenanthrylcarbonyl group.
  • acyloxy group refers to an oxy group having the above-mentioned C1-C16 acyl group, and is preferably bound to an acyl group having a C1-C16 substituent such as acetoxy group, ethylacyloxy group and phenylacyloxy group. It represents an oxy group, and is preferably an acetoxy group, a tert-butylcarbonyloxy group or a phenylcarbonyloxy group.
  • alkylcarbonyloxy group refers to an oxy group having the above alkylcarbonyl group, and is also included in the alias acyloxy group.
  • methylcarbonyloxy group, ethylcarbonyloxy group, n-propylcarbonyloxy group, isopropylcarbonyloxy group, n-butylcarbonyloxy group, isobutylcarbonyloxy group, tert-butylcarbonyloxy group, n-pentylcarbonyloxy group examples thereof include (C1-C6 alkyl) carbonyloxy groups such as isopentylcarbonyloxy group and hexylcarbonyloxy group, with acetoxy group and tert-butylcarbonyloxy group being preferred.
  • arylcarbonyloxy group refers to an oxy group having the above arylcarbonyl group, and is also included in the alias acyloxy group.
  • Examples thereof include (C6-C14 aryl) carbonyloxy groups such as a 4,4-dioxanaphthalenylcarbonyloxy group, an indanylcarbonyloxy group and a phenanthrylcarbonyloxy group, and a phenylcarbonyloxy group is preferable.
  • alkoxycarbonyl group refers to a carbonyl group having the above alkoxy group, for example, a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a butoxycarbonyl group, an isobutoxycarbonyl group, Examples thereof include (C1-C6 alkoxy) carbonyl groups such as tert-butoxycarbonyl group, pentyloxycarbonyl group, isopentyloxycarbonyl group and hexyloxycarbonyl group, preferably methoxycarbonyl group, ethoxycarbonyl group and tert-butoxycarbonyl group. And more preferably a tert-butoxycarbonyl group.
  • the “aralkyloxycarbonyl group” refers to a carbonyl group having the above aralkyloxy, and examples thereof include a benzyloxycarbonyl group, a phenethyloxycarbonyl group, a naphthylmethyloxycarbonyl group and a fluorenylmethyloxycarbonyl group. (C6-C20 aralkyl) oxycarbonyl group can be mentioned, and benzyloxycarbonyl group is preferable.
  • the “saturated heterocyclic group” is a monocyclic ring having at least one (preferably 1 to 5, more preferably 1 to 3) hetero atom selected from a nitrogen atom, an oxygen atom and a sulfur atom.
  • the “unsaturated heterocyclic group” is a monocyclic group having at least one (preferably 1 to 5, more preferably 1 to 3) hetero atom selected from a nitrogen atom, an oxygen atom and a sulfur atom. It represents a cyclic or polycyclic fully unsaturated or partially unsaturated heterocyclic group, and represents an imidazolyl group, a thienyl group, a pyrrolyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an isothiazolyl group, a thiadiazolyl group, an oxadiazolyl group, a pyrazolyl group.
  • Triazolyl group Triazolyl group, tetrazolyl group, pyridyl group, pyrazyl group, pyrimidinyl group, pyridazinyl group, indolyl group, isoindolyl group, indazolyl group, triazolopyridyl group, benzimidazolyl group, benzoxazolyl group, benzothiazolyl group, benzothienyl group, furanyl Group, benzofuranyl group, purini Group, quinolyl group, isoquinolyl group, quinazolinyl group, quinoxalyl group, methylenedioxyphenyl group, ethylenedioxyphenyl group, dihydrobenzofuranyl group, and other 5- to 10-membered unsaturated heterocyclic groups, and preferably imidazolyl group Group, pyrazolyl group, thiazolyl group, isoxazolyl group, oxazolyl group and furanyl
  • the “saturated heterocyclic oxy group” refers to an oxy group having the saturated heterocyclic group, and examples thereof include a morpholinyloxy group, a 1-pyrrolidinyloxy group, a piperidinooxy group and a piperazinyloxy group. , 4-methyl-1-piperazinyloxy group, tetrahydrofuranyloxy group, tetrahydropyranyloxy group, tetrahydrothiophenyloxy group, thiazolidinyloxy group, oxazolidinyloxy group and the like, and preferably An azetidinyloxy group and a pyrrolidinyloxy group.
  • X 1 represents C, N, O or S, preferably C, N or S, more preferably N or S. And more preferably N.
  • X 2 represents C or N, preferably C.
  • the combination of X 1 and X 2 is preferably X 1 , C, N, O or S, and X 2 is C or N. More preferably, X 1 represents C, N or S, X 2 represents C or N, further preferably X 1 represents N or S, X 2 represents C, and most preferably X 1 represents N. , X 2 represents C.
  • X 1 and X 2 and (X 1, X 2) there preferably (N, C), (S , C), (O, C), (C, N) , More preferably (N, C), (S, C), (C, N), even more preferably (N, C), (S, C), and most preferably (N, C). is there.
  • R 1 represents an optionally substituted C1-C6 alkyl group.
  • the "C1-C6 alkyl group which may have a substituent (s)" represented by R 1 is preferably a methyl group, an ethyl group or a tert-butyl group, more preferably a methyl group or an ethyl group, and A methyl group is preferred.
  • R 1 is preferably a methyl group or an ethyl group.
  • R 1 is more preferably a methyl group.
  • R 2 is a hydrogen atom, a halogen atom, a cyano group, a nitro group, a carboxyl group, or a C1-C6 alkyl which may have a substituent.
  • C2-C6 alkenyl group which may have a substituent
  • C2-C6 alkynyl group which may have a substituent
  • C3-C10 cycloalkyl group which may have a substituent
  • C4-C10 cycloalkenyl group optionally substituted C1-C6 alkoxy group
  • optionally substituted C6-C14 aromatic hydrocarbon group optionally substituted 4 to It represents a 10-membered saturated heterocyclic group or a 5- to 10-membered unsaturated heterocyclic group which may have a substituent.
  • the “C1-C6 alkyl group” in the “C1-C6 alkyl group optionally having substituent (s)” represented by R 2 is preferably a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group.
  • Examples of the "substituent" in the "C1-C6 alkyl group which may have a substituent” represented by R 2 include the substituents described above, but preferably a halogen atom, a cyano group and a hydroxyl group.
  • C1-C6 alkylamino group C3-C10 cycloalkyl group optionally having C1-C6 alkoxy group, C6-C10 aromatic hydrocarbon group, optionally C1-C6 alkyl group 4 to 10 Membered saturated heterocyclic group, more preferably substituted with a halogen atom, a C1-C6 alkoxy group, a C1-C6 alkylamino group, a C3-C7 cycloalkyl group, a phenyl group, and 1 to 3 C1-C6 alkoxy groups.
  • the “C1-C6 alkyl group optionally having substituent (s)” represented by R 2 is preferably a halogen atom, a C1-C6 alkoxy group optionally having substituent (s), or optionally having a substituent (s).
  • a C3-C10 cycloalkyl group which may have a C1-C6 alkoxy group, a C6-C10 aromatic hydrocarbon group, and a 4- to 10-membered saturated heterocyclic group which may have a C1-C6 alkyl group
  • a C1-C6 alkyl group which may have a substituent, more preferably a fluorine atom, a methoxy group, a dimethylamino group, a cyclopentyl group, a phenyl group, a 3,5-dimethoxyphenyl group and N-isopropyl-
  • a C1-C6 alkyl group which may have a substituent selected from the group consisting of a 2-pyrrolidylmethyl group, more preferably a methyl group, an ethyl group, an n-propyl group, an isopropyl group, and an n-butyl group.
  • the “C2-C6 alkenyl group” of the “C2-C6 alkenyl group which may have a substituent” represented by R 2 is preferably a vinyl group, a 1-propenyl group, an allyl group or an isopropenyl group, A vinyl group, an isopropenyl group and an allyl group are more preferable, and a vinyl group and an allyl group are more preferable.
  • Examples of the “substituent” in the “C2-C6 alkenyl group which may have a substituent” represented by R 2 include the substituents described above, but preferably a halogen atom, a cyano group and a hydroxyl group. Is more preferable, a chlorine atom and a fluorine atom are more preferable, and a fluorine atom is still more preferable.
  • the "C2-C6 alkenyl group which may have a substituent (s)" for R 2 is preferably a C2-C6 alkenyl group which may have a halogen atom, more preferably a vinyl group or 1-propenyl. Group, a 2-methyl-2-propenyl group, and more preferably a vinyl group.
  • the “C2-C6 alkynyl group” of the “C2-C6 alkynyl group optionally having a substituent” represented by R 2 is preferably an ethynyl group or a 1-propynyl group.
  • Examples of the "substituent" in the "C2-C6 alkynyl group which may have a substituent” represented by R 2 include the substituents described above, preferably a halogen atom and a hydroxyl group, More preferably, they are a fluorine atom and a chlorine atom.
  • the “C2-C6 alkynyl group which may have a substituent (s)” represented by R 2 is preferably an ethynyl group or a 1-propynyl group.
  • the “C1-C6 alkoxy group” of the “C1-C6 alkoxy group optionally having a substituent” represented by R 2 is preferably a methoxy group, an ethoxy group, an n-propoxy group, an isopropoxy group, n- Examples thereof include C1-C6 alkoxy groups such as butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, pentyloxy group, isopentyloxy group and hexyloxy group, preferably methoxy group and ethoxy group. A methoxy group is preferred.
  • Examples of the “substituent” in the “C1-C6 alkoxy group which may have a substituent” represented by R 2 include the substituents described above, but preferably a halogen atom or a hydroxyl group, More preferably, they are a fluorine atom and a chlorine atom.
  • the “C1-C6 alkoxy group which may have a substituent (s)” represented by R 2 is preferably a methoxy group or an ethoxy group, more preferably a methoxy group.
  • the “C3-C10 cycloalkyl group” in the “C3-C10 cycloalkyl group which may have a substituent” represented by R 2 is preferably cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl Group, more preferably a cyclopropyl group, a cyclopentyl group and a cyclohexyl group, and further preferably a cyclopropyl group.
  • Examples of the “substituent” in the “C3-C10 cycloalkyl group which may have a substituent” represented by R 2 include the substituents described above, but preferably a halogen atom, a hydroxyl group, A C1-C6 alkyl group which may have a substituent, a C1-C6 alkoxy group which may have a substituent, and a C1-C6 haloalkyl group which may have a substituent, more preferably a fluorine atom, a chlorine atom, a hydroxyl group, a methyl group , Ethyl group, n-propyl group, isopropyl group, fluoromethyl group, difluoromethyl group, trifluoromethyl group, methoxy group and ethoxy group.
  • the “C3-C10 cycloalkyl group which may have a substituent” represented by R 2 is preferably a hydroxyl group, a C1-C6 alkyl group which may have a substituent or a substituent group.
  • C1-C6 alkyl group, C1-C6 haloalkyl group and C1-C6 alkoxy group which may have a substituent selected from the group consisting of C3-C10 cycloalkyl groups, more preferably hydroxyl group and C1- C3-C7 cycloalkyl which may have a substituent selected from the group consisting of C6 alkyl group, C1-C6 haloalkyl group and C1-C6 alkoxy group.
  • Most preferred are a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and a 1- (trifluoromethyl) cyclopropyl group.
  • Examples of the “C4-C10 cycloalkenyl group” in the “C4-C10 cycloalkenyl group optionally having a substituent” represented by R 2 include a cyclobutenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, cyclodecenyl. Groups, etc., preferably a C4-C7 cycloalkenyl group, more preferably a cyclopentenyl group.
  • Examples of the “substituent” in the “C4-C10 cycloalkenyl group optionally having substituent (s)” represented by R 2 include the substituents described above, but preferably a halogen atom, and more preferably Are fluorine atoms and chlorine atoms.
  • the “C4-C10 cycloalkenyl group which may have a substituent (s)” represented by R 2 is preferably a C4-C10 cycloalkenyl group, more preferably a C4-C7 cycloalkenyl group, and more preferably It is a cyclopentenyl group.
  • the "C6-C10 aromatic hydrocarbon group" of the "C6-C10 aromatic hydrocarbon group which may have a substituent (s)" represented by R 2 is preferably a phenyl group, a naphthyl group or a tetrahydronaphthyl group. And more preferably a phenyl group.
  • Examples of the “substituent” in the “C6-C10 aromatic hydrocarbon group which may have a substituent” represented by R 2 include the substituents described above, but a halogen atom is preferable. , And more preferably a fluorine atom or a chlorine atom.
  • the “C6-C10 aromatic hydrocarbon group which may have a substituent (s)” represented by R 2 is preferably a C6-C10 aromatic hydrocarbon group, and more preferably a phenyl group.
  • the “4- to 10-membered saturated heterocyclic group” of the “4- to 10-membered saturated heterocyclic group which may have a substituent” represented by R 2 is preferably a nitrogen atom, an oxygen atom or a sulfur atom. It is a monocyclic or bicyclic 4- to 10-membered saturated heterocyclic group having 1 to 5 heteroatoms selected, more preferably 1 heteroatom selected from nitrogen atom, oxygen atom and sulfur atom. It is a monocyclic 4- to 7-membered saturated heterocyclic group having 3 to 3, more preferably an aziridinyl group, a pyrrolidinyl group, a piperidinyl group, and a tetrahydropyranyl group.
  • Examples of the “substituent” in the “4- to 10-membered saturated heterocyclic group which may have a substituent” represented by R 2 include the substituents described above, but the substituent is preferable. May be C1-C6 alkyl group, C1-C6 alkenyl group, (C1-C6 alkyl) carbonyl group, (C1-C6 alkoxy) carbonyl group, C3-C10 cycloalkyl group, C6-C10 aromatic hydrocarbon group A 4- to 10-membered saturated heterocyclic group, a 5- to 10-membered unsaturated heterocyclic group, more preferably a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C1-C6 alkoxy-C1-C6 alkyl group, C7-C16 aralkyl group, C1-C6 alkenyl group, (C1-C6 alkyl) carbonyl group, (C1-C6 alk
  • the “4- to 10-membered saturated heterocyclic group which may have a substituent” represented by R 2 is preferably N-tert-butoxycarbonylazetidinyl group, N-isopropylazetidinyl group, N -Acetylazetidinyl group, N-methylpyrrolidinyl group, N-ethylpyrrolidinyl group, N-acetylpyrrolidinyl group, N-isopropylpyrrolidinyl group, N-pyridinepyrrolidinyl group, N-2 -Methoxyethyl-pyrrolidinyl group, N-cyclopropylpyrrolidinyl group, N-oxetanylpyrrolidinyl group, N-benzylpyrrolidinyl group, N-carboxylate-azetidinyl group, N-difluoroethyl-pyrrolidinyl group, N -Prop-2-enyl-
  • the “5- to 10-membered unsaturated heterocyclic group” of the “5- to 10-membered unsaturated heterocyclic group which may have a substituent” represented by R 2 is preferably a nitrogen atom, an oxygen atom and sulfur. It is a monocyclic or bicyclic 5- to 10-membered unsaturated heterocyclic group having 1 to 5 heteroatoms selected from atoms, and more preferably a hetero atom selected from nitrogen atom, oxygen atom and sulfur atom. It is a monocyclic 5- to 7-membered unsaturated heterocyclic group having 1 to 3 atoms, and more preferably a pyridinyl group.
  • Examples of the “substituent” in the “5- to 10-membered unsaturated heterocyclic group which may have a substituent” represented by R 2 include the substituents described above, but preferably a halogen atom, It is a hydroxyl group or a C1-C6 alkyl group, more preferably a methyl group, an ethyl group, a hydroxyl group, a fluorine atom or a chlorine atom.
  • the “5- to 10-membered unsaturated heterocyclic group which may have a substituent” represented by R 2 is preferably a 5- to 10-membered unsaturated heterocyclic group, more preferably a pyridinyl group and N. A methylpyridinyl group.
  • R 2 preferably has a hydrogen atom, a halogen atom, a cyano group, a C1-C6 alkyl group (a halogen atom, a C1-C6 alkoxy group, a C1-C6 alkylamino group, a C3-C10 cycloalkyl group, a substituent)
  • a C6-C10 aromatic hydrocarbon group a substituent selected from the group consisting of a 4- to 10-membered saturated heterocyclic group which may have a substituent
  • a C2-C6 alkenyl group Having a substituent selected from the group consisting of a halogen atom, a cyano group and a hydroxyl group
  • a C2-C6 alkynyl group having a substituent selected from the group consisting of a halogen atom and a hydroxyl group
  • C3-C10 cycloalkyl group which may have a substituent selected from the group consisting of a hydroxyl
  • R 2 is more preferably a hydrogen atom, a C1-C6 alkyl group (a halogen atom, a C1-C6 alkoxy group, a C1-C6 alkylamino group, a C3-C10 cycloalkyl group, or a C6-C10 which may have a substituent).
  • Aromatic hydrocarbon group optionally substituted substituent selected from the group consisting of 4- to 10-membered saturated heterocyclic group), C2-C6 alkenyl group (halogen atom, cyano) Group, may have a substituent selected from the group consisting of a hydroxyl group), C3-C10 cycloalkyl group (a substituent selected from the group consisting of a hydroxyl group, a C1-C6 alkyl group, a C1-C6 alkoxy group) Or a C6-C14 aromatic hydrocarbon group (which may have a halogen atom as a substituent).
  • R 2 is more preferably a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group, or a C3-C10 cycloalkyl group, a C6-C14 aromatic hydrocarbon group.
  • R 2 is more preferably a hydrogen atom or a C1-C6 alkyl group.
  • R 2 is more preferably a hydrogen atom or a C1-C3 alkyl group.
  • R 2 is more preferably a hydrogen atom, a chlorine atom, a methyl group, a vinyl group or a phenyl group.
  • R 2 is more preferably a hydrogen atom, a methyl group, or a vinyl group.
  • R 2 is most preferably a hydrogen atom.
  • L, m and n each independently represent 0 or 1.
  • L + m + n is 1, 2 or 3, preferably 1 or 2, and more preferably 2.
  • the compound represented by the general formula (I) may be referred to as the compound (I). Further, the compound represented by the general formula (II) may be referred to as the compound (II).
  • Compound (I) and compound (II) are represented by formula (I) and formula (II), wherein X 1 represents C, N, O or S, X 2 represents C or N, and R 1 has a substituent.
  • X 1 represents C, N, O or S
  • X 2 represents C or N
  • R 1 has a substituent.
  • R 1 may have a hydrogen atom, a cyano group, a nitro group, a halogen atom, a carboxyl group, an optionally substituted C1-C6 alkyl group, or an optionally substituted group.
  • X 1 represents C, N or S
  • X 2 represents C or N
  • R 1 represents a C1-C6 alkyl group
  • R 2 Is a hydrogen atom, a halogen atom, a cyano group, a C1-C6 alkyl group (a halogen atom, a C1-C6 alkoxy group, a C1-C6 alkylamino group, a C3-C10 cycloalkyl group, or a C6-C10 which may have a substituent).
  • Aromatic hydrocarbon group optionally substituted substituent selected from the group consisting of 4- to 10-membered saturated heterocyclic group
  • C2-C6 alkenyl group (halogen atom, cyano) Group may have a substituent selected from the group consisting of a hydroxyl group), C2-C6 alkynyl group (may have a substituent selected from the group consisting of a halogen atom, a hydroxyl group), C3 -C10 cycloalkyl Group (which may have a substituent selected from the group consisting of a hydroxyl group, a C1-C6 alkyl group and a C1-C6 alkoxy group), a C3-C10 cycloalkenyl group (which may have a halogen atom as a substituent) Good), a C1-C6 alkoxy group (which may have a substituent selected from the group consisting of a halogen atom, a cyano group and a hydroxyl group), a C
  • 4-10 membered saturated heterocyclic group (C1-C6 alkyl group, C1-C6 haloalkyl group, C1-C6 alkoxy-C1-C6 alkyl group, C7-C16 aralkyl group, C1-C6 alkenyl group) , C1-C6 alkylcarbonyl group, C1-C6 alkoxycarbonyl group, C3-C10 cycloalkyl group, 4- to 10-membered saturated heterocyclic group, 5- It may have a substituent selected from the group consisting of 0-membered unsaturated heterocyclic groups) 4- to 10-membered unsaturated heterocyclic groups (group consisting of halogen atom, hydroxyl group, C1-C6 alkyl group) May have a substituent selected from), and l + m + n is 1 or 2.
  • X 1 represents C, N or S
  • X 2 represents C or N
  • R 1 represents a C1-C6 alkyl group
  • R 2 Represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group, or a C3-C10 cycloalkyl group, a C6-C14 aromatic hydrocarbon group
  • 1 + m + n is 1 or 2.
  • X 1 represents C, N or S
  • X 2 represents C or N
  • R 1 represents a C1-C6 alkyl group
  • R 2 Represents a hydrogen atom, a chlorine atom, a methyl group, a vinyl group or a phenyl group
  • l + m + n is 1 or 2.
  • X 1 represents N or S
  • X 2 represents C
  • R 1 represents a C1-C6 alkyl group
  • R 2 represents a hydrogen atom
  • It represents a chlorine atom, a methyl group, a vinyl group or a phenyl group
  • l + m + n is 1 or 2.
  • X 1 represents N or S
  • X 2 represents C
  • R 1 represents a C1-C3 alkyl group
  • R 2 represents a hydrogen atom or a methyl group.
  • Vinyl group and 1 + m + n is 1 or 2.
  • X 1 represents N
  • X 2 represents C
  • R 1 represents a methyl group
  • R 2 represents a hydrogen atom
  • l + m + n is 2.
  • the compound (I) and the compound (II) have 1 + m + n substituents R 2 .
  • R 2 substituents
  • R 1 represents a C1-C6 alkyl group which may have a substituent
  • R 2 is a hydrogen atom, a cyano group, a nitro group, a halogen atom, a carboxyl group, a C1-C6 alkyl group which may have a substituent, a C2-C6 alkenyl group which may have a substituent, C2-C6 alkynyl group optionally having substituent (s), C1-C6 alkoxy group optionally having substituent (s), C3-C10 cycloalkyl group optionally having substituent (s), C6-C14 aromatic hydrocarbon Represents a 4- to 10-membered saturated heterocyclic group or a 5- to 10-membered unsaturated heterocyclic group.
  • X 1a , X 2a , X 3a and R 1 are the same as defined above.
  • compounds of formula (I) include, for example: -Methyl 4-chloro-1H-imidazole-5-carboxylate-ethyl 5-chloro-1-methyl-1H-imidazole-4-carboxylate-methyl 4-chlorothiazole-5-carboxylate-ethyl 5-chloro-1 -Methylpyrazole-4-carboxylate
  • the compound (I) and compound (II) or a salt thereof may be amorphous or crystalline, and the compound of the present invention or a salt thereof may be a single crystal form or a polymorphic mixture. Included.
  • the crystal can be produced by applying a known crystallization method to crystallize.
  • Compound (I) and compound (II) or a salt thereof may be a solvate (for example, a hydrate or the like) or a non-solvate, and both are compound (I) and compound (II). ) Or a salt thereof.
  • a compound labeled with an isotope eg, 2H, 3H, 13C, 14C, 35S, 125I, etc. is also included in the compound of the present invention or a salt thereof.
  • the salt of compound (I) and compound (II) means a pharmaceutically acceptable salt, and examples thereof include a base addition salt and an acid addition salt.
  • compound (I) or a salt thereof can be obtained by irradiating a reaction system containing the compound (II) or a salt thereof, a diazotizing agent, and hydrochloric acid with light.
  • the reaction is carried out by using an aminoazole carboxylate derivative represented by the general formula (II) or a salt thereof, or a solvate thereof in a solvent in the presence of hydrochloric acid to form a diazotizing agent. And irradiating it with light having a UV wavelength of 200 to 495 nm, whereby a chloroazole carboxylate derivative represented by the general formula (I) or a salt thereof, or a solvate thereof is produced. .
  • the reaction is considered to proceed in two steps: diazotization of compound (II) or a salt thereof and chlorination of the diazotized product. That is, a step (step A) of obtaining a compound represented by the general formula (III) by diazotizing an aminoazole carboxylate derivative represented by the following general formula (II) or a salt thereof or a solvate thereof.
  • step A of obtaining a compound represented by the general formula (III) by diazotizing an aminoazole carboxylate derivative represented by the following general formula (II) or a salt thereof or a solvate thereof.
  • chlorination is carried out by irradiating light into a reaction system containing hydrochloric acid to produce a compound represented by the general formula (I), which is a two-step process (process B).
  • process B a two-step process
  • the method of the present invention can be represented by the following reaction formula.
  • the present invention provides a compound represented by the general formula (II) by diazotizing an aminoazole carboxylate derivative represented by the general formula (II) or a salt thereof, or a solvate thereof, and chlorinating by irradiation with light in a reaction system containing hydrochloric acid.
  • step A is a step of obtaining a diazo compound (III) by treating the compound represented by the general formula (II) or a salt thereof, or a solvate thereof with a diazotizing agent.
  • the acid is not particularly limited as long as it can be used with the diazotizing agent, and examples thereof include hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, methanesulfonic acid and a mixed solvent thereof. , Preferably hydrochloric acid. This acid may be the acid used in the salt of the compound represented by the general formula (II).
  • the compound represented by the general formula (II) is a salt such as hydrochloride, it is not necessary to add an acid.
  • an acid for example, 1 to 1000 molar equivalents can be added to the compound (II), preferably 1 to 20 molar equivalents, more preferably 1 to 12 molar equivalents, and further preferably It is 1 to 8 molar equivalents.
  • the solvent used in step A is not particularly limited as long as it does not inhibit the reaction, but includes water, methanol, ethanol, isopropanol, N, N-dimethylformamide (DMF), N-methyl-2-pyrrolidone (NMP), Tetrahydrofuran (THF), 1,4-dioxane, chloroform, methylene chloride and the like and mixed solvents thereof are mentioned, and water or a mixed solvent of water and a solvent other than water is preferable.
  • the diazotizing agent is not particularly limited as long as it can form a reaction intermediate nitrosonium ion, and examples thereof include alkyl nitrite metal salts, nitrite esters, and nitrosonium salts.
  • alkyl metal nitrite include sodium nitrite and potassium nitrite;
  • examples of the nitrites include ethyl nitrite, isobutyl nitrite, tert-butyl nitrite and isoamyl nitrite.
  • Examples of the nitrosonium salt include nitrosonium tetrafluoroborate and the like.
  • the compounding amount of the diazotizing agent is not particularly limited, but for example, it is usually 1 to 1000 molar equivalents, preferably 1 to 100 molar equivalents, and more preferably 1 to 3 molar equivalents relative to the compound (II).
  • the alkyl nitrite metal salt may be used as an aqueous solution.
  • the reaction temperature in step A is not particularly limited, but usually it can be carried out within the range of the freezing point of the solvent to 50 ° C., preferably ⁇ 10 ° C. to room temperature.
  • the reaction time is not particularly limited, it is generally within 1 day after adding the diazotizing agent, more preferably within 12 hours, further preferably within 3 hours, and most preferably within 1 hour.
  • the step B is a step of irradiating the diazo compound (III) with light to chlorinate hydrochloric acid as a chlorine source for the Sandmeyer reaction to obtain the compound (I).
  • the amount of hydrochloric acid added to the reaction system in step B is not particularly limited, but since chloride ion in hydrochloric acid is used in this reaction, at least 1 is usually added to the compound (II) or salt thereof added in step A. Molar equivalents are necessary.
  • the total amount of hydrochloric acid added in step A and step B is not limited, but is usually 1 to 1000 molar equivalents, preferably 1 to 20 molar equivalents, and more preferably 3 to the compound (II) or salt thereof added in step A. To 20 molar equivalents, more preferably 3 to 12 molar equivalents, and most preferably 12 molar equivalents.
  • the concentration of hydrochloric acid (chloride ion) in the reaction solution is not limited, but it is usually 0.1 to 12 N, preferably 1 to 12 N, because the hydrolysis reaction of the carboxylic acid occurs when the definition of hydrochloric acid increases. It is more preferably 2N to 9N, still more preferably 3N.
  • Step B is a production method characterized by irradiating with light after introducing the diazotizing agent and hydrochloric acid into the reaction system, and preferably after efficiently using the diazotizing agent and hydrochloric acid used in the step,
  • the reaction solution may be moved to a container that can be irradiated with light and then irradiated with light.
  • the light used for the reaction may be ultraviolet light to visible light, and is not particularly limited as long as it is a light source containing this wavelength, but a light source such as a UV lamp, an LED, a fluorescent lamp, or a halogen lamp is usually used. Can be used.
  • the reaction temperature is generally 0-100 ° C, preferably room temperature to 50 ° C.
  • the reaction time is generally 1 minute to 1 week, preferably 10 minutes to 3 days, more preferably 30 minutes to 3 days, and further preferably 30 minutes to 24 hours.
  • the light used for the reaction can be from ultraviolet rays to visible rays.
  • Ultraviolet rays are classified into far ultraviolet rays (wavelength 10-200 nm) and near ultraviolet rays (wavelength 200-380 nm), and the ultraviolet rays used in the present invention are preferably near ultraviolet rays.
  • Near-ultraviolet rays are further divided into UV-A (wavelength 315-380 nm), UV-B (wavelength 280-315 nm), and UV-C (wavelength 200-280 nm).
  • UV-A, UV-B, and UV-C are all contained in the ultraviolet rays contained in sunlight, but UV-A and UV-B pass through the ozone layer and reach the surface of the earth.
  • the near-ultraviolet rays used in the present invention preferably include all near-ultraviolet rays of UV-A, UV-B and UV-C.
  • the wavelength of the light used for the reaction is from near-ultraviolet light of 200-495 nm to visible light, preferably near-ultraviolet light of 200-380 nm, more preferably 280-380 nm, further preferably Is 315-380 nm, most preferably 365 nm.
  • step A when the acid is added in step A, for example, 1 to 1000 molar equivalents of acid can be added to the compound (II) or the salt thereof added in step A.
  • the total amount of hydrochloric acid added in step A and step B is preferably 1 to 20 molar equivalents relative to compound (II) or a salt thereof added in step A.
  • the amount of the diazotizing agent in step A is 1 to 1000 molar equivalents with respect to the compound (II) or its salt added in step A, and the concentration of hydrochloric acid in the reaction solution used in step B is 0.1 to 12 N.
  • the wavelength of the light used in is preferably 200-495 nm.
  • the reaction temperature is not limited, it can usually be carried out within the range of the freezing point of the solvent to 50 ° C.
  • the reaction time is not limited, it is usually within 1 day after the addition of the diazotizing agent.
  • step A when the acid is added in step A, 1 to 20 molar equivalents can be added to the compound (II) or salt thereof added in step A.
  • the total amount of hydrochloric acid added in step A and step B is preferably 3 to 20 molar equivalents relative to compound (II) or a salt thereof added in step A.
  • the amount of the diazotizing agent in step A is 1 to 100 molar equivalents with respect to the compound (II) or its salt added in step A, and the concentration of hydrochloric acid in the reaction solution used in step B is 1 to 12N.
  • the wavelength of the emitted light is 200-380 nm.
  • the reaction temperature is preferably ⁇ 10 ° C. to room temperature.
  • the reaction time is preferably within 12 hours after adding the diazotizing agent.
  • step A when the acid is added in step A, 1 to 12 molar equivalents can be added to the compound (II) or salt thereof added in step A.
  • the total amount of hydrochloric acid added in step A and step B is preferably 3 to 12 molar equivalents relative to compound (II) or a salt thereof added in step A.
  • the amount of the diazotizing agent in step A is 1 to 3 molar equivalents with respect to the compound (II) or its salt added in step A, and the concentration of hydrochloric acid in the reaction solution used in step B is 2 to 9N.
  • the wavelength of the emitted light is preferably 280-380 nm.
  • the reaction temperature is preferably ⁇ 10 ° C. to room temperature.
  • the reaction time is preferably within 3 hours after adding the diazotizing agent.
  • the condition of this step is to add 1 to 8 molar equivalents to the compound (II) or its salt added in step A when hydrochloric acid is added in step A.
  • the total amount of hydrochloric acid added in step A and step B is preferably 12 molar equivalents relative to compound (II) or a salt thereof added in step A.
  • the amount of the diazotizing agent in step A is 1 to 3 molar equivalents with respect to the compound (II) or salt thereof added in step A, the concentration of hydrochloric acid in the reaction solution used in step B is 3N, and the amount of light used in this step is The wavelength is preferably 315-380 nm.
  • the reaction temperature is preferably ⁇ 10 ° C. to room temperature.
  • the reaction time is preferably within 1 hour after adding the diazotizing agent.
  • X 1 represents C, N, O or S
  • X 2 represents C or N
  • R 1 has a substituent.
  • a C1-C6 alkyl group R 2 may have a hydrogen atom, a cyano group, a nitro group, a halogen atom, a carboxyl group, an optionally substituted C1-C6 alkyl group, or an optionally substituted group.
  • C2-C6 alkenyl group optionally substituted C2-C6 alkynyl group, optionally substituted C1-C6 alkoxy group, optionally substituted C3-C10 cycloalkyl group, substituted A C4-C10 cycloalkenyl group which may have a group, a C6-C14 aromatic hydrocarbon group which may have a substituent, a 4- to 10-membered saturated heterocyclic group which may have a substituent, or a substituent Represents a 5- to 10-membered unsaturated heterocyclic group which may have a group, and l + m + n is 1 It is 2 or 3.
  • step A When the acid is added in step A, preferably 1 to 1000 molar equivalents can be added to the compound (II) or salt thereof added in step A.
  • the total amount of hydrochloric acid added in step A and step B is preferably 1 to 20 molar equivalents relative to compound (II) or a salt thereof added in step A.
  • Solvents include water, methanol, ethanol, isopropanol, N, N-dimethylformamide (DMF), N-methyl-2-pyrrolidone (NMP), tetrahydrofuran (THF), 1,4-dioxane, chloroform, methylene chloride and the like.
  • the amount of diazotizing agent is 1 to 1000 molar equivalents
  • the concentration of hydrochloric acid in the reaction solution used in step B is 0.1 to 12 N
  • the wavelength of light used in this step is 200 to 495 nm. Is preferred.
  • the reaction temperature is not limited, it can usually be carried out within the range of the freezing point of the solvent to 50 ° C.
  • the reaction time is not limited, it is usually within 1 day after the addition of the diazotizing agent.
  • X 1 represents C, N or S
  • X 2 represents C or N
  • R 1 represents a C1-C6 alkyl group
  • R 2 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group, or a C3-C10 cycloalkyl group, a C6-C14 aromatic hydrocarbon group
  • l + m + n is 1 or 2.
  • the total amount of hydrochloric acid added in step A and step B is preferably 3 to 20 molar equivalents relative to compound (II) or a salt thereof added in step A.
  • Solvents include water, methanol, ethanol, isopropanol, N, N-dimethylformamide (DMF), N-methyl-2-pyrrolidone (NMP), tetrahydrofuran (THF), 1,4-dioxane, chloroform, methylene chloride and the like. It is a mixed solvent, and the amount of the diazotizing agent is 1 to 100 molar equivalents with respect to the compound (II) or its salt added in step A, and the concentration of hydrochloric acid in the reaction solution used in step B is 1 to 12N.
  • the wavelength of light used in the process is preferably 200-380 nm.
  • the reaction temperature is preferably ⁇ 10 ° C. to room temperature.
  • the reaction time is usually within 12 hours after the addition of the diazotizing agent.
  • X 1 represents C, N or S
  • X 2 represents C or N
  • R 1 represents a C1-C6 alkyl group
  • R 2 represents a hydrogen atom, a methyl group, a vinyl group, a phenyl group or a chlorine atom
  • 1 + m + n is 1 or 2.
  • 1 to 20 molar equivalents can be preferably added to the compound (II) or the salt thereof added in step A.
  • the total amount of hydrochloric acid added in step A and step B is preferably 3 to 20 molar equivalents relative to compound (II) or a salt thereof added in step A.
  • Solvents include water, methanol, ethanol, isopropanol, N, N-dimethylformamide (DMF), N-methyl-2-pyrrolidone (NMP), tetrahydrofuran (THF), 1,4-dioxane, chloroform, methylene chloride and the like. It is a mixed solvent, and the amount of the diazotizing agent is 1 to 100 molar equivalents with respect to the compound (II) or its salt added in step A, and the concentration of hydrochloric acid in the reaction solution used in step B is 1 to 12N.
  • the wavelength of light used in the process is preferably 200-380 nm.
  • the reaction temperature is preferably ⁇ 10 ° C. to room temperature.
  • the reaction time is usually within 12 hours after the addition of the diazotizing agent.
  • X 1 represents N or S
  • X 2 represents C
  • R 1 represents a C1-C3 alkyl group
  • R 2 represents It represents a hydrogen atom, a methyl group or a vinyl group
  • l + m + n is 2.
  • the acid is added in step A, preferably 1 to 12 molar equivalents can be added to the compound (II) or salt thereof added in step A.
  • the total amount of hydrochloric acid added in step A and step B is preferably 3 to 12 molar equivalents relative to compound (II) or a salt thereof added in step A.
  • the solvent is water or a mixed solvent with a solvent other than water, and the amount of the diazotizing agent is 1 to 3 molar equivalents relative to the compound (II) or its salt added in step A, in the reaction liquid used in step B. It is preferable that the concentration of hydrochloric acid is 2 to 9 N, and the wavelength of light used in this step is 280 to 380 nm.
  • the reaction temperature is preferably ⁇ 10 ° C. to room temperature.
  • the reaction time is preferably within 3 hours after adding the diazotizing agent.
  • X 1 represents N
  • X 2 represents C
  • R 1 represents a methyl group
  • R 2 represents a hydrogen atom
  • l + m + n is 2.
  • an acid preferably 1 to 8 molar equivalents can be added to the compound (II) or salt thereof added in step A.
  • the total amount of hydrochloric acid added in step A and step B is preferably 12 molar equivalents relative to compound (II) or a salt thereof added in step A.
  • the solvent is water or a mixed solvent with a solvent other than water, and the amount of the diazotizing agent is preferably 1 to 3 molar equivalents with respect to the compound (II) or its salt added in step A, and used in step B.
  • the concentration of hydrochloric acid in the reaction solution is preferably 3N, and the wavelength of light used in this step is preferably 315-380 nm.
  • the reaction temperature can be preferably from ⁇ 10 ° C. to room temperature, and the reaction time is preferably within 1 hour from the addition of the diazotizing agent.
  • step B part or all of the reaction of step A and the reaction of step B may proceed in parallel. Therefore, in the present invention, even if the step B is started by light irradiation after the reaction of the step A is started or the step B is started by light irradiation before the reaction of the step A is finished, the step B is started by the light irradiation at the same time as the start of the step A. You may start the process B. Therefore, in the present invention, since the step B is performed without isolating and purifying the diazo compound represented by the general formula (III) obtained in the step A, in the present invention, after the step A, the same reaction system is used. Step B may be performed.
  • the compound (I) obtained by the method of the present invention comprises, as impurities, (1) diazo compound, (2) ester hydrolyzate, (3) solvent used in reaction or purification, (4) diazonium salt and raw material, and production. It may contain by-products that have reacted with substances, reagents or solvents.
  • the compound (I) can be purified by post-treatment according to a conventional method after completion of the reaction.
  • the post-treatment used here is not particularly limited, but for example, filtration of the precipitate after the reaction, filtration of the precipitate after adding the neutralizing agent to the reaction solution, extraction operation by adding the neutralizing agent to the reaction solution After carrying out, the solvent can be concentrated, and the residue of the concentration can be purified by column chromatography.
  • the compound represented by the general formula (I) of the present invention can be produced, for example, by the following production method or the method shown in Examples.
  • the method for purifying the compound represented by the general formula (I) of the present invention is not limited to these reaction examples, and known separation and purification means such as concentration, concentration under reduced pressure, crystallization, solvent extraction, It can be isolated and purified by reprecipitation, chromatography and the like.
  • the photoirradiation reaction was carried out using Handheld UV Lamp UVM-57 (Analytical Queena, 302 nm, 6 W) and Handy UV Lamp SLUV-6 (Azuwan, 254 nm, 365 nm switching type, 6 W each).
  • the LCMS spectrum was measured under the following conditions using SQD manufactured by Waters.
  • Step 1 Synthesis of methyl 4-chloro-1H-imidazole-5-carboxylate 1 (Step 1) Methanesulfonic acid (90 mL) was added to a solution of 4-amino-1H-imidazole-5-carboxamide (52 g) in methanol (300 mL), and the mixture was stirred at 110 ° C. for 3 days. The solution was concentrated under reduced pressure, 5N aqueous sodium hydroxide solution was added, the mixture was extracted with ethyl acetate, and the organic layer was washed with saturated brine.
  • Step 2 To the methyl 4-amino-1H-imidazole-5-carboxylate (4.5 g) obtained in the above Step 1 was added 12N hydrochloric acid (20 mL), and sodium nitrite (3.3 g) was added. Was added dropwise under ice cooling, and the mixture was stirred at the same temperature for 15 minutes. After the reaction solution was flatly transferred to a glass dish, UV light (302 nm, 6 W) was irradiated from a distance of 3 cm overnight.
  • the reaction solution was transferred to a Petri dish with a diameter of 10 cm, and UV light (365 nm, 6 W) was irradiated for 2 cm. Irradiation was carried out at a temperature of 30 ° C. for 17 hours. Dimethyl 1H-imidazole-4,5-dicarboxylate was added as an internal standard substance, and the product yield was determined by LCMS.
  • the reaction solution was neutralized with potassium carbonate, and the precipitated solid was collected by filtration. The residue was washed with purified water and then dried by heating overnight to give methyl 4-chloro-1H-imidazole-5-carboxylate (453 mg, 56%).
  • Example 3-15 Synthesis of methyl 4-chloro-1H-imidazole-5-carboxylate 3-15
  • Table 1 shows the results of the reaction performed under the reaction conditions of Example 2 while changing the total concentration / equivalent of hydrochloric acid and the wavelength of the light source. After stirring the reaction mixture overnight, dimethyl 1H-imidazole-4,5-dicarboxylate was added as an internal standard substance, and the product yield was determined by LCMS. In this Example 2-15, it was found that the yield was improved when light irradiation was performed, as compared with Comparative Example 1.
  • Example 18 Synthesis of methyl 4-chlorothiazole-5-carboxylate Methyl 4-aminothiazole-5-carboxylate (500 mg) and concentrated hydrochloric acid (1.84 mL) were added to a pear-shaped flask, and sodium sulfite (261 mg) was added under ice cooling. A water (1.84 mL) solution was added slowly. The reaction solution was stirred for 30 minutes under ice cooling, and then transferred to a petri dish using 6N hydrochloric acid (3.16 mL). UV light (365 nm, 6 W) was irradiated on the petri dish at 30 ° C. for 1 hour. The reaction solution was neutralized with potassium carbonate and extracted with ethyl acetate.
  • step 1 Synthesis of methyl 1- (5- (methoxycarbonyl) -1H-imidazol-4-yl) -1H-1,2,4-triazole-3-carboxylate (step 1) Methyl 4-amino-1H-imidazole-5 Water (6.0 mL) was added to carboxylate hydrochloride (3.10 g) and stirred to obtain a suspension. Sodium nitrite (1.55g) was added and stirred until the reaction suspension dissolved. The reaction solution was extracted with a mixed solvent of chloroform / isopropanol (4/1) and dried over sodium sulfate.
  • Step 2 To a solution of methyl 4-diazo-4H-imidazole-5-carboxylate (100 mg) obtained in Step 1 above in methanol (2 mL) and water (0.2 mL), methyl 2-isocyanoacetate ( 0.1 mL) was added and stirred for 1 hour.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/JP2019/042005 2018-10-26 2019-10-25 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 Ceased WO2020085504A1 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2018-202226 2018-10-26
JP2018202226 2018-10-26
JP2019075118 2019-04-10
JP2019-075118 2019-04-10

Publications (1)

Publication Number Publication Date
WO2020085504A1 true WO2020085504A1 (ja) 2020-04-30

Family

ID=70331140

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2019/042005 Ceased WO2020085504A1 (ja) 2018-10-26 2019-10-25 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
PCT/JP2019/041942 Ceased WO2020085493A1 (ja) 2018-10-26 2019-10-25 新規なインダゾール化合物又はその塩

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/041942 Ceased WO2020085493A1 (ja) 2018-10-26 2019-10-25 新規なインダゾール化合物又はその塩

Country Status (5)

Country Link
US (1) US12065430B2 (https=)
EP (1) EP3871673B1 (https=)
JP (1) JP7451419B2 (https=)
TW (1) TWI831855B (https=)
WO (2) WO2020085504A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3909950A1 (en) * 2020-05-13 2021-11-17 Basf Se Heterocyclic compounds for the control of invertebrate pests
WO2021228594A1 (en) * 2020-05-13 2021-11-18 Basf Se Heterocyclic compounds for the control of invertebrate pests
WO2023031781A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312413B2 (en) 2018-08-29 2026-01-01 Acerta Pharma Bv Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-enol)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
UA129778C2 (uk) 2019-10-28 2025-07-30 Мерк Шарп Енд Доум Елелсі Низькомолекулярні інгібітори g12c-мутантного kras
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
WO2021215545A1 (en) * 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
WO2021215544A1 (en) * 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
CN111943879A (zh) * 2020-08-03 2020-11-17 南通大学 一种（3s，4r）3-氨基-4（甲氧基甲基）吡咯烷-1-甲酸叔丁酯及其合成方法
EP4573095A1 (en) 2022-08-17 2025-06-25 Treeline Biosciences, Inc. Pyridopyrimidine kras inhibitors
CN115260103B (zh) * 2022-09-19 2023-01-17 苏州美诺医药科技有限公司 一种4,5-二卤代-1-(二氟甲基)-1h-咪唑的制备方法
TW202430179A (zh) 2022-11-21 2024-08-01 美商樹線生物科學公司 螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑
TW202528315A (zh) 2023-09-21 2025-07-16 美商樹線生物科學公司 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑
AU2024361909A1 (en) 2023-10-20 2026-03-26 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
CN120718285A (zh) * 2025-08-14 2025-09-30 东营市黄河燃气有限责任公司 油气净化二氧化碳pamam接枝离子液体的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014111559A (ja) * 2012-07-04 2014-06-19 Nissan Chem Ind Ltd ピラゾール誘導体および有害生物防除剤
WO2018087527A1 (en) * 2016-11-08 2018-05-17 Cancer Research Technology Limited Pyrimidinone derivatives as cdc7 inhibitors

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034075A (en) 1972-07-03 1977-07-05 Allen & Hanburys Limited Quinaldic acid derivatives
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
WO2005019177A1 (en) 2003-08-14 2005-03-03 Icos Corporation Aminopiperidine amide derivatives as vla-1 integrin antagonists and uses thereof
US8278313B2 (en) 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
WO2010064705A1 (ja) 2008-12-05 2010-06-10 大日本住友製薬株式会社 Ｈ４受容体アンタゴニスト作用を有する新規７位置換ジヒドロピラノピリミジン誘導体
US20100331305A1 (en) 2009-06-24 2010-12-30 Genentech, Inc. Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
HUE039713T2 (hu) 2012-06-08 2019-02-28 Sensorion H4 receptor inhibitorok tinnitus kezelésére
CN105189505B (zh) 2012-09-12 2019-03-22 默克夏普&多梅有限公司 用作抗菌剂的三环促旋酶抑制剂
WO2014164543A1 (en) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
CA2904393A1 (en) 2013-03-15 2014-09-25 Araxes Pharma Llc Covalent inhibitors of kras g12c
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
DK2981963T3 (en) 2013-04-05 2017-02-27 Dolby Laboratories Licensing Corp COMPRESSION APPARATUS AND PROCEDURE TO REDUCE QUANTIZATION NOISE USING ADVANCED SPECTRAL EXTENSION
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
EP3055290B1 (en) 2013-10-10 2019-10-02 Araxes Pharma LLC Inhibitors of kras g12c
US20160318866A1 (en) 2013-12-19 2016-11-03 Bayer Pharma Aktiengesellschaft Substituted bipiperidinyl derivatives
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
JP2017528498A (ja) * 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
WO2016049565A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Compositions and methods for inhibition of ras
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
AU2016229294B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
US10428064B2 (en) 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2017015562A1 (en) 2015-07-22 2017-01-26 Araxes Pharma Llc Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356351A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017070256A2 (en) 2015-10-19 2017-04-27 Araxes Pharma Llc Method for screening inhibitors of ras
KR20180081596A (ko) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
KR102444509B1 (ko) 2016-05-18 2022-09-19 미라티 테라퓨틱스, 인크. Kras g12c 억제제
WO2018022897A1 (en) 2016-07-27 2018-02-01 Padlock Therapeutics, Inc. Covalent inhibitors of pad4
WO2018064510A1 (en) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3523289A1 (en) 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
CN110366550A (zh) 2016-12-22 2019-10-22 美国安进公司 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573966A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused n-heterocyclic compounds and methods of use thereof
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
JOP20190186A1 (ar) 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
EP3621968A1 (en) 2017-05-11 2020-03-18 Astrazeneca AB Heteroaryl compounds that inhibit g12c mutant ras proteins
AU2018273356B2 (en) 2017-05-22 2021-09-16 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
CN110869357A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 化合物及其用于治疗癌症的使用方法
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
CN107556289A (zh) 2017-06-22 2018-01-09 天津国际生物医药联合研究院 一种氯苯‑吡啶类化合物及其应用
AU2018329920B2 (en) 2017-09-08 2022-12-01 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
GB201715342D0 (en) 2017-09-22 2017-11-08 Univ Nottingham Compounds
CN109670389B (zh) 2017-10-16 2023-04-07 富士通株式会社 评价人脸图像中的光照条件的方法和设备
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
LT3710439T (lt) 2017-11-15 2023-05-10 Mirati Therapeutics, Inc. Kras g12c inhibitoriai
WO2019099703A1 (en) 2017-11-16 2019-05-23 Sidecar Therapeutics, Inc. Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds
US10597405B2 (en) 2017-12-08 2020-03-24 Astrazeneca Ab Chemical compounds
TW201942116A (zh) 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
IL276232B2 (en) 2018-03-02 2024-04-01 Otsuka Pharma Co Ltd Pyrazine derivatives, pharmaceutical compositions comprising them and their use for treating diseases
WO2019185525A1 (en) 2018-03-28 2019-10-03 Bayer Pharma Aktiengesellschaft 4-(3-amino-6-fluoro-1h-indazol-5-yl)-1,2,6-trimethyl-1,4-dihydropyridine-3,5-dic arbonitrile compounds for treating hyperproliferative disorders
CA3098574A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
TW202012415A (zh) 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
US11285156B2 (en) 2018-06-12 2022-03-29 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
AU2019320945C1 (en) 2018-08-16 2021-09-30 F. Hoffmann-La Roche Ag Fused ring compounds
JP6648797B2 (ja) 2018-10-04 2020-02-14 株式会社三洋物産 遊技機
TW202033518A (zh) 2018-10-15 2020-09-16 美商美國禮來大藥廠 Kras g12c 抑制劑
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
PE20260440A1 (es) 2018-11-09 2026-02-19 Hoffmann La Roche Compuestos de anillo fusionado
AU2019384118B2 (en) 2018-11-19 2025-06-12 Amgen Inc. KRAS G12C inhibitors and methods of using the same
EP3887373A1 (en) 2018-11-29 2021-10-06 Araxes Pharma LLC Compounds and methods of use thereof for treatment of cancer
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
EP3919483A4 (en) 2019-01-29 2022-02-09 Brightgene Bio-medical Technology Co., Ltd. HETEROCYCLIC BENZOPYRIDONE COMPOUND AND USE THEREOF
WO2020177629A1 (zh) 2019-03-01 2020-09-10 劲方医药科技(上海)有限公司 螺环取代的嘧啶并环类化合物，其制法与医药上的用途
KR102934231B1 (ko) 2019-03-05 2026-03-06 아스트라제네카 아베 항암제로 유용한 융합 삼환식 화합물
KR20220012255A (ko) 2019-04-28 2022-02-03 젠플리트 테라퓨틱스 (상하이) 아이엔씨. 옥사아자퀴나졸린-7(8h)-케톤 화합물, 이의 제조 방법 및 이의 약학적 응용
JP7502337B2 (ja) 2019-05-20 2024-06-18 カリフォルニア インスティチュート オブ テクノロジー Ｋｒａｓ ｇ１２ｃインヒビター及びその使用
WO2020234103A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft Identification and use of kras inhibitors
CN114437065A (zh) 2019-05-21 2022-05-06 益方生物科技(上海)股份有限公司 杂环化合物，其制备方法和用途
TW202110837A (zh) 2019-05-24 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 氫化吡啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用
WO2020239077A1 (zh) 2019-05-29 2020-12-03 上海翰森生物医药科技有限公司 含氮杂环类衍生物调节剂、其制备方法和应用
CN113396147B (zh) 2019-05-31 2024-06-18 上海翰森生物医药科技有限公司 芳香杂环类衍生物调节剂、其制备方法和应用
PH12021553058A1 (en) 2019-06-06 2022-07-25 Hutchison Medipharma Ltd Tricyclic compounds and their use
AU2020308353B9 (en) 2019-06-24 2024-01-25 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of KRAS G12C
US12421236B2 (en) 2019-06-25 2025-09-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
CN110256421A (zh) 2019-06-26 2019-09-20 微境生物医药科技(上海)有限公司 Kras-g12c抑制剂
WO2021000885A1 (zh) 2019-07-01 2021-01-07 江苏恒瑞医药股份有限公司 喹唑啉酮类衍生物、其制备方法及其在医药上的应用
JP7756069B6 (ja) 2019-08-02 2025-11-27 上海済▲ユウ▼医薬科技股▲フン▼有限公司 四環式化合物、その調製と使用の方法
CN112341457A (zh) 2019-08-07 2021-02-09 北京加科思新药研发有限公司 Kras突变蛋白抑制剂
CN114174298B (zh) 2019-08-14 2023-08-01 正大天晴药业集团南京顺欣制药有限公司 哒嗪酮并嘧啶类衍生物及其医药用途
CN112390797A (zh) 2019-08-15 2021-02-23 微境生物医药科技(上海)有限公司 新型螺环类K-Ras G12C抑制剂
WO2021031952A1 (zh) 2019-08-16 2021-02-25 劲方医药科技(上海)有限公司 氧代六元环并嘧啶类化合物，其制法与医药上的用途
CN114269735B (zh) 2019-08-26 2024-02-23 南京创济生物医药有限公司 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
CN112430234B (zh) 2019-08-26 2023-04-28 信达生物制药(苏州)有限公司 一种新型kras g12c蛋白抑制剂及其制备方法和用途
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
WO2021043322A1 (zh) 2019-09-06 2021-03-11 正大天晴药业集团南京顺欣制药有限公司 氮杂环庚烷并嘧啶类衍生物及其医药用途
US20220402916A1 (en) 2019-09-18 2022-12-22 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
WO2021052499A1 (zh) 2019-09-20 2021-03-25 上海济煜医药科技有限公司 稠合吡啶酮类化合物及其制备方法和应用
TW202115062A (zh) 2019-09-25 2021-04-16 大陸商北京加科思新藥研發有限公司 Kras突變蛋白抑制劑
WO2021058018A1 (en) 2019-09-29 2021-04-01 Beigene, Ltd. Inhibitors of kras g12c
WO2021063346A1 (zh) 2019-09-30 2021-04-08 上海迪诺医药科技有限公司 Kras g12c抑制剂及其应用
CN112694475B (zh) 2019-10-23 2025-09-23 苏州泽璟生物制药股份有限公司 环烷基类和杂环烷基类抑制剂及其制备方法和应用
EP4048671B1 (en) 2019-10-24 2026-03-18 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
UA129778C2 (uk) 2019-10-28 2025-07-30 Мерк Шарп Енд Доум Елелсі Низькомолекулярні інгібітори g12c-мутантного kras
CN114585610A (zh) 2019-10-28 2022-06-03 日本曹达株式会社 2,6-二氧代-3,6-二氢嘧啶化合物以及农业园艺用杀菌剂、杀线虫剂、及医疗用·动物用抗真菌剂
JP7601869B2 (ja) 2019-10-30 2024-12-17 ▲勁▼方医▲薬▼科技（上海）有限公司 置換された複素環－環系化合物、その調製方法及び医薬への応用
WO2021084765A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd 4-aminobut-2-enamide derivatives and salts thereof
US20230023023A1 (en) 2019-10-31 2023-01-26 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
CN113286794B (zh) 2019-11-04 2024-03-12 北京加科思新药研发有限公司 Kras突变蛋白抑制剂
CN114630832A (zh) 2019-11-15 2022-06-14 四川海思科制药有限公司 一种嘧啶并环衍生物及其在医药上的应用
CN112824410A (zh) 2019-11-21 2021-05-21 苏州泽璟生物制药股份有限公司 氮杂七元环类抑制剂及其制备方法和应用
CN113614080B (zh) 2019-11-29 2022-06-28 苏州信诺维医药科技股份有限公司 Kras g12c抑制剂化合物及其用途
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
WO2021109737A1 (zh) 2019-12-02 2021-06-10 上海璎黎药业有限公司 一种含氧杂环化合物、其制备方法及应用
WO2021113595A1 (en) 2019-12-06 2021-06-10 Beta Pharma, Inc. Phosphorus derivatives as kras inhibitors
PT3886991T (pt) 2019-12-11 2022-10-17 Lilly Co Eli Inibidores de kras g12c
WO2021120045A1 (en) 2019-12-18 2021-06-24 InventisBio Co., Ltd. Heterocyclic compounds, preparation methods and uses thereof
CN114761408B (zh) 2019-12-19 2023-09-15 贝达药业股份有限公司 Kras g12c抑制剂及其在医药上的应用
IL293962B2 (en) 2019-12-19 2025-10-01 Jacobio Pharmaceuticals Co Ltd Mutant KRAS protein inhibitors
CA3164995A1 (en) 2019-12-20 2021-06-24 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2021120890A1 (en) 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
CN113045565A (zh) 2019-12-27 2021-06-29 微境生物医药科技(上海)有限公司 新型K-Ras G12C抑制剂
CN115003668A (zh) 2020-01-21 2022-09-02 南京明德新药研发有限公司 作为kras抑制剂的大环类化合物
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
WO2021215545A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
WO2021219072A1 (zh) 2020-04-30 2021-11-04 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
US20230357277A1 (en) 2020-09-22 2023-11-09 Mirati Therapeutics, Inc. Kras g12d inhibitors
EP4247807A4 (en) 2020-11-23 2024-10-16 Merck Sharp & Dohme LLC 6,7-DIHYDRO-PYRANO[2,3-D PYRIMIDINE AS INHIBITORS OF THE KRAS G12C MUTANT
US20240124478A1 (en) 2020-11-23 2024-04-18 Merck Sharp & Dohme Llc SPIROCYCLIC-SUBSTITUTED 6,7-DIHYDRO-PYRANO[2,3-d]PYRIMIDINE INHIBITORS OF KRAS G12C MUTANT
JP2023553492A (ja) 2020-12-15 2023-12-21 ミラティ セラピューティクス， インコーポレイテッド アザキナゾリン汎ＫＲａｓ阻害剤
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
EP4291199A4 (en) 2021-02-09 2025-06-18 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
BR112023016299A2 (pt) 2021-02-16 2023-11-28 L Livermore Nat Security Llc Composições e métodos para inibir kras
EP4322954A4 (en) 2021-04-16 2025-01-29 Merck Sharp & Dohme LLC SMALL MOLECULAR INHIBITORS OF THE KRAS G12D MUTANT
US20240262842A1 (en) 2021-04-27 2024-08-08 Merck Sharp & Dohme Llc Small molecule inhibitors of kras g12c mutant
US20240246968A1 (en) 2021-04-27 2024-07-25 Merck Sharp & Dohme Llc Small molecule inhibitors of kras g12c mutant
EP4347606A4 (en) 2021-05-28 2025-04-02 Merck Sharp & Dohme LLC SMALL MOLECULES INHIBITING THE G12C KRAS MUTANT
EP4347041A1 (en) 2021-05-28 2024-04-10 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
WO2022256459A1 (en) 2021-06-01 2022-12-08 Quanta Therapeutics, Inc. Kras modulators and uses thereof
EP4436571A4 (en) 2021-11-24 2025-10-15 Merck Sharp & Dohme Llc SMALL MOLECULE INHIBITORS OF KRAS MUTATIONAL PROTEINS
US20260083750A1 (en) 2022-08-26 2026-03-26 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014111559A (ja) * 2012-07-04 2014-06-19 Nissan Chem Ind Ltd ピラゾール誘導体および有害生物防除剤
WO2018087527A1 (en) * 2016-11-08 2018-05-17 Cancer Research Technology Limited Pyrimidinone derivatives as cdc7 inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BUTLER, R. N., CHEMICAL REVIEWS, vol. 75, no. 2, 1975, pages 241 - 257 *
IMOYANO, E. L. ET AL., EUR.J.ORG.CHEM., 2008, pages 3377 - 3381 *
ISMITH, M. R. ET AL., J,ORG,CHEM., vol. 74, 2009, pages 9372 - 9380 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3909950A1 (en) * 2020-05-13 2021-11-17 Basf Se Heterocyclic compounds for the control of invertebrate pests
WO2021228594A1 (en) * 2020-05-13 2021-11-18 Basf Se Heterocyclic compounds for the control of invertebrate pests
WO2023031781A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers

Also Published As

Publication number Publication date
TWI831855B (zh) 2024-02-11
JP7451419B2 (ja) 2024-03-18
US20210395234A1 (en) 2021-12-23
EP3871673A4 (en) 2022-06-22
EP3871673A1 (en) 2021-09-01
TW202029960A (zh) 2020-08-16
EP3871673B1 (en) 2024-01-03
US12065430B2 (en) 2024-08-20
WO2020085493A1 (ja) 2020-04-30
JPWO2020085493A1 (ja) 2021-09-09

Similar Documents

Publication Publication Date Title
WO2020085504A1 (ja) 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
TW519538B (en) Heterocyclic compounds and medical use thereof
TW201841889A (zh) 尼拉帕尼(niraparib)之製備方法
JP2007534638A5 (https=)
CN104411686B (zh) 4-[5-(吡啶-4-基)-1h-1,2,4-三唑-3-基]吡啶-2-腈的制造方法及中间体
RU2563630C1 (ru) Способ получения гидрохлорида 1-(3,4-дихлор-2-фторфениламино)-7-метоксихиназолин-6-илокси)пиперидин-1-ил)проп-2-ен-1-она и используемых в нем промежуточных соединений
Franck et al. Pd-catalyzed intramolecular direct arylations at high temperature
CN104662002A (zh) 取代脲类化合物的合成方法
Lee et al. Concise total syntheses of paullone and kenpaullone via cyanide-catalyzed intramolecular imino-stetter reaction
CN107383017A (zh) 依鲁替尼高效制备方法
CN114262321B (zh) 一种双稳态光调控小分子蛋白降解剂、制备方法及应用
CN105073752B (zh) 制备三环化合物的方法以及可通过所述制备方法制备的三环化合物
Sapegin et al. Dibenzo [b, f] pyrazolo [1, 5-d][1, 4] oxazepines: Facile Construction of a Rare Heterocyclic System via Tandem Aromatic Nucleophilic Substitution–Smiles Rearrangement–Denitrocyclization
CA2975072A1 (en) Method for producing pyrazinecarboxamide compound and synthetic intermediate thereof
WO2010098496A1 (en) Process for producing tetrahydrotriazolopyridine derivative
Tabata et al. Site-selective radical reactions of kinetically stable open-shell singlet diradicaloid difluorenoheteroles with tributyltin hydride and azo-based radical initiators
Palmer et al. Large-scale asymmetric synthesis of the 3, 6, 7, 8-tetrahydrochromeno [7, 8-d] imidazole BYK 405879: a promising candidate for the treatment of acid-related diseases
CN109384785B (zh) 吡咯并吡啶酮类衍生物、其制备方法及其在医药上的用途
US20240262839A1 (en) Scalable anion capture macrocycles
Zhou et al. Solvent-free and catalyst-free method for the synthesis of 2, 4, 5-triarylimidazoles under microwave irradiation
JP7094942B2 (ja) ベンズイミダゾール誘導体の製造方法
JPH0539233A (ja) 芳香族弗素化合物の製造法
CN110669027B (zh) 化合物和其酯、其制备方法和用途
JP2010502581A (ja) 化学方法
CN109305957B (zh) 苯基吡啶类化合物及其在dpp-4酶抑制剂的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19875165

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19875165

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP